Published in Drug Week, March 30th, 2007
The net loss for the fourth quarter of 2006 was $8.3 million, or $0.16 per share, compared with a net loss for the fourth quarter of 2005 of $4.6 million, or $0.10 per share. Results for the fourth quarter of 2006 include non-cash stock-based compensation expenses of $935,000 recognized in accordance with SFAS 123R. Results for the fourth quarter of 2005 do not include SFAS 123R compensation expenses because SFAS 123R is effective beginning January 1, 2006. Revenues for the three months ended December 31, 2006 were $18,000, down from $1.4 million in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.